Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV Cohort Study

Antiviral Therapy

Volumn 13, Issue 3, 2008, Pages 455-460

  Rauch, Andri ^a,b   Gaudieri, Silvana ^b,c   Evison, John ^a   Nolan, David ^b   Cavassini, Matthias ^d   Weber, Rainer ^e   James, Ian ^b   Furrer, Hansjakob ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b MURDOCH UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENDER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MIXED INFECTION; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T CELL DEPLETION; VIRUS TRANSMISSION; BLOOD; GENETICS; IMMUNOLOGY; MIDDLE AGED; SWITZERLAND; UPREGULATION; VIRUS LOAD;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; SWITZERLAND; UP-REGULATION; VIRAL LOAD;

EID: 47249165699     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
2. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497.
3. Benhamou Y, Bochet M, Di M, V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-1058.
4. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138:197-207.
5. Giordano TP, Kramer JR, Souchek J, Richardson P, El Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004; 164:2349-2354.
6. Graham CS, Baden LR, Yu E, et al. Influence of human immumodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569.
7. Dutoit V, Ciuffreda D, Comte D, Gonvers JJ, Pantaleo G. Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection. Eur J Immunol 2005; 35:3493-3504.
8. + T cells in HIV/HCV co-infected patients. Gut 2006; 55:1484-1487.
9. Thomas DL, Rich JD, Schuman P, et al. Multicenter evaluation of hepatitis C RNA levels among female injection drug users. J Infect Dis 2001; 183:973-976.
10. Daar ES, Lynn H, Donfield S, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquit Immune Defic Syndr 2001; 26:466-472.
11. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34:1193-1199.
12. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994; 84:1020-1023.
13. Fishbein DA, Lo Y, Netski D, Thomas DL, Klein RS. Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users. J Acquir Immune Defic Syndr 2006; 41:471-476.
14. Sherman KE, O'Brien J, Gutierrez AG, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993; 31:2679-2682.
15. Thomas DL, Astemborski J, Vlahov D, et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000; 181:844-851.
16. Ticehurst JR, Hamzeh F, Thomas DL. Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J Clin Microbiol 2007; 45:2426-2433.
17. Berger A, von Depka PM, Doerr HW, Rabenau H, Weber B. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. J Med Virol 1996; 48:339-343.
18. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362:2095-2100.
19. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36:S1-S2.
20. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-150.
21. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
22. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
23. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007; 46:22-31.
24. Braitstein P, Zala C, Yip B, et al. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis 2006; 193:259-268.
25. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177:783-785.
26. Puoti M, Gargiulo F, Roldan EQ, et al. Liver damage and kinetics of hepatitis C virus and numan immunodeficiency virus replication during the early phases of combination antiretroviral treatment. J Infect Dis 2000; 181:2033-2036.
27. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002; 16:1915-1923.
28. Cooper CL, Cameron DW Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis 2002; 35:873-879.
29. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302:659-662.
30. + T-cell count in individuals coinfected with HIV-1. Blood 2005; 105:1170-1178.
31. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713.